Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Novel Eye Wash Solution for DED Treatment

11 novembre 2026 aggiornato da: Jiaxu Hong, Eye & ENT Hospital of Fudan University

A single-center, randomized, participant-masked, placebo-controlled, parallel-group clinical trial designed to evaluate the effectiveness and safety of a novel eye wash solution for the treatment of dry eye disease

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

30

Fase

  • Prima fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Shanghai, Cina
        • Fudan Eye, Ear, Nose and Throat Hospital
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Age of at least 18 years at the time of signing the informed consent. Provision of written informed consent.
  • Tear film break-up time (TBUT) < 10 seconds at both Visit 0 and Visit 1. Ocular Surface Disease Index (OSDI) score ≥ 13 at both Visit 0 and Visit 1. Meibomian gland dysfunction (MGD) score ≥ 3 at Visit 0 or Visit 1.
  • Presence of cloudy meibum; or 3 or 4 out of 5 meibomian glands expressible upon eyelid compression; or meibomian gland dropout count ≥ 5 at both Visit 0 and Visit 1.
  • Meibomian gland dysfunction scoring: MGD is scored based on the secretion of the central 5 meibomian glands of the lower eyelid. Each gland is scored from 0 to 3 (0 = normal; 1 = thick, yellow-white particles; 2 = paste-like secretion; 3 = no secretion or obstruction), with a total score of 0-15 [12].
  • Total corneal fluorescein staining score of 1 < X < 10 (sum of inferior, superior, central, nasal, and temporal regions) according to the National Eye Institute (NEI) grading system at both Visit 0 and Visit 1.
  • At both Visit 0 and Visit 1, at least one eye (the same eye) must meet all criteria of items 3, 4, 5, and 6 above.
  • Ability and willingness to follow instructions, including participation in all study assessments and visits.

Exclusion Criteria:

  • Any clinically significant abnormal findings on slit-lamp examination of the ocular surface at both Visit 0 and Visit 1, or any findings that, in the investigator's judgment, may affect study parameters, which may include ocular trauma, history of ocular trauma, or anterior membrane disease.
  • History of Stevens-Johnson syndrome; use of any oral medications known to cause dry eyes (e.g., antihistamines, antidepressants, etc.) within 1 month prior to Visit 0, or expected instability during the study period.
  • Active ocular infection; use of any topical antibiotics or topical steroids within 14 days prior to the visit, or potential need for such treatment during the study. Any other eyelid margin treatments, such as meibomian gland expression, systemic antibiotics (e.g., tetracyclines), and oral supplements for eye diseases (e.g., lutein) must remain stable for 14 days prior to the visit and throughout the study period.
  • Receipt of LipiFlow, intense pulsed light (IPL), or any other procedures affecting the meibomian glands within 1 month prior to Visit 1.
  • Abnormal eyelid structure preventing complete eyelid closure, including entropion, ectropion, or floppy eyelid syndrome, which may cause partial conjunctival exposure or affect eyelid blinking function.
  • Placement or removal of a permanent punctal plug within 3 months prior to Visit 1 (or 6 months for dissolvable plugs); or expected placement or removal of a punctal plug at this visit, or expected dissolution of the punctal plug during the study.
  • Dry eye caused by scarring, radiation injury, alkali burns, cicatricial pemphigoid, or destruction of conjunctival goblet cells (commonly seen in vitamin A deficiency).
  • Ocular or periocular malignancy.
  • Corneal epithelial defect; significant confluent staining or filaments in any part of the cornea.
  • History of herpes keratitis.
  • Significant ocular allergy symptoms, or expected persistent allergic conditions during the study.
  • Diagnosis of active ocular or systemic infection (bacterial, viral, or fungal) accompanied by fever requiring antibiotic treatment.
  • Use of contact lenses within 14 days prior to Visit 0, or expected use of contact lenses during the study.
  • Any intraocular, corneal, or ocular laser surgery within the past 6 months, or any planned ocular and/or eyelid surgery during the study.
  • Employees of the clinical trial site directly involved in the management, administration, or support of this trial, or immediate family members of the same trial site.
  • Women who are pregnant, breastfeeding, or planning to become pregnant.
  • For women of childbearing potential, refusal to undergo urine pregnancy testing at Visit 0, Visit 1, Visit 2, and Visit 3 (or early termination visit) will be considered a refusal of testing. Non-childbearing potential is defined as permanently sterilized (e.g., hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or postmenopausal (no menstruation for 12 consecutive months).
  • Women of childbearing potential not using effective contraception. Acceptable contraceptive methods include: hormonal oral contraceptives, implantable contraceptive devices, injectable contraceptives, or transdermal contraceptives; mechanical spermicides combined with barrier devices such as a diaphragm or condom; intrauterine devices; or surgical sterilization of the partner. For women who are not sexually active, abstinence may be considered an effective contraceptive method; however, if the subject becomes sexually active during the trial, she must agree to use appropriate contraception as defined above for the remainder of the trial.
  • Presence of an uncontrolled systemic disease, in the investigator's judgment. Known allergic reaction to the investigational drug or its components. Significant ocular or periocular rosacea that, in the investigator's judgment, interferes with the trial (e.g., clinically significant facial induration).
  • Pterygium in either eye.
  • Current participation in an investigational drug or device study, or use of an investigational drug or device within 60 days after Visit 1.
  • Non-use of any lipid-based artificial tears (e.g., perfluorohexyloctane ophthalmic solution, etc.), no application of warm compresses, and no use of any eye drops and/or "TrueTear™" device (intranasal tear neurostimulator) within 3 days prior to this visit.
  • Presence of systemic immune diseases, such as systemic lupuserythematosus, rheumatoid arthritis, ankylosing spondylitis, Sjögren's syndrome, etc.
  • Best-corrected visual acuity ≥ 4.3 in both eyes at Visit 0 and Visit 1 (5-point recording method on the international standard logarithmic visual acuity chart at 5 meters).
  • Any condition or circumstance (including language barriers) that, in the investigator's judgment, may place the subject at significant risk, may interfere with study results, or may significantly hinder the subject's participation in the study.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore placebo: Braccio placebo

Saline (NaCl 0.9 %), one drop per eye, 3 times daily (TID) for 28 days.

Sperimentale: Eye Wash Solution Arm

0.2% DHA eye wash solution, one drop per eye, 3 times daily (TID) for 28 days.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Corneal Fluorescein Staining (CFS) Score
Lasso di tempo: Baseline (Visit 1) to Day 28 (Visit 3)

Change from baseline in corneal fluorescein staining score (total score 0-15) in the study eye.

Baseline (Visit 1) to Day 28 (Visit 3)
Change in Ocular Surface Disease Index (OSDI) Score
Lasso di tempo: Baseline (Visit 1) to Day 28 (Visit 3)

Change from baseline in OSDI score (ranging from 0 to 100) to assess dry eye symptoms.

Baseline (Visit 1) to Day 28 (Visit 3)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 novembre 2026

Completamento primario (Stimato)

1 novembre 2026

Completamento dello studio (Stimato)

1 novembre 2027

Date di iscrizione allo studio

Primo inviato

11 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

11 novembre 2026

Primo Inserito (Effettivo)

16 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

11 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • FDEENT-20261111

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .